|
| Report (number of cases and grades) | Antibody used | Immunostaining percentage | Correlations with clinicopathological features | Other correlations | Survival analysis |
|
| Korkolopoulou et al. [30] (111 patients: 25 grade II, 15 III, and 71 IV) | Rabbit polyclonal anti-p-p70S6K (Thr421/Ser424) ab (specific for p70 subunit) (SCB), diluted 1 : 250 for IHC and 1 : 200 for WB | 99.1% (99/111) showed nuclear staining | No significant correlation | p-p70S6K with
(i) cytoplasmic p-AKT
(ii) p-mTOR (marginal)
(iii) VEGF | No significant correlation |
| Yang et al. [12] (96 patients: 16 grade II, 35 III, and 45 IV) | Rabbit polyclonal anti-p-S6 (Ser235/236) ab (CST), at a concentration of 0.125 Ig/mL (IHC) | 82.3% (79/96) cytoplasmic | p-S6 with
(i) tumor grade
(ii) lower KPS score | — | (i) p-S6 with worse prognosis
(ii) Multivariate analysis: p-S6 as an independent prognostic factor |
| Li et al. [14] (87 patients: 27 grade I-II, 24 III, and 36 IV) | Rabbit monoclonal anti-p-p70S6K (Thr389) ab (EP), diluted 1 : 50 (IHC) | (i) 72.4% (63/87) nuclear and/or cytoplasmic
(ii) 41.7% of grade IV showed strong expression | p-p70S6K with tumor grade | — | — |
| McBride et al. [35] (45 patients: 22 astrocytomas grade II) | (i) Rabbit polyclonal anti-p-S6 (Ser235/236) ab (SCT), diluted 1 : 200 (IHC)
(ii) Rabbit polyclonal anti-p-S6 (Ser240/244) ab (CST), diluted 1 : 200 (IHC) | (i) p-S6 (Ser235/236): 76% (29/38)
(ii) p-S6 (Ser240/244): 76% (29/38) | — | p-S6 (Ser235/236) with
(i) p-PRAS40
(ii) p-S6 (Ser240/244) p-S6 (Ser240/244) with
(iii) PTEN methylation
(iv) inversely PTEN expression | (i) p-S6 (Ser235/236) with OS
(ii) p-S6 (Ser240/244) with OS |
| Annovazzi et al. [18] (54 patients: 10 grade II, 10 III, and 34 IV) | Rabbit polyclonal anti-p-S6 (Ser240/244) ab (CST), diluted 1 : 100 for IHC. Not provided for WB | (i) 0%, 30%, and 82.3% in grade II, III, and IV, respectively
(ii) Nuclear in grade II and III but mainly cytoplasmic in grade IV | p-S6 with tumor grade | p-S6 IHC with
(i) p-S6 WB
(ii) Ki-67
(iii) inversely with Beclin 1 | No significant correlation |
| Ermoian et al. [36] (71 patients: 28 grade II, 17 III, and 26 IV | Anti-p-S6 ab (CST) | Not provided | p-S6 unrelated to tumor grade | No significant correlation | No significant correlation |
| Pelloski et al. [22] (268 grade IV) | Anti p-p70S6K ab (CST), diluted 1 : 1000 (WB) | Not provided | — | p-p70S6K with
(i) p-ERK
(ii) p-mTOR
(iii) p-AKT
(iv) PTEN
(v) YKL-40 | (i) p-p70S6K with shorter OS
(ii) Multivariate analysis: not retained as an independent prognostic factor |
| Riemenschneider et al. [23] (29 grade IV) | (i) Mouse monoclonal anti-p-p70S6K (Thr389) ab (CST), diluted 1 : 200 (IHC)
(ii)Rabbit monoclonal anti-p-S6 (Ser235/236) ab (CST), diluted 1 : 200 (IHC) | Not provided | — | (i) p-p70S6K
with p-AKT
(ii) p-S6 with p-AKT | — |
| Ckakravarti et al. [25] (11 grade II, 13 III, and 56 IV) | Anti-p-p70S6K (Thr389) ab (CST), diluted 1 : 50 (WB) | 39.1% (36/92) of grade IV | p-p70S6K with tumor grade | p-p70S6K with
(i) p-PI3K
(ii) p-AKT
(iii) inversely cCas3 | p-p70S6K with
(i) adverse outcome
(ii) reduced time to death
Multivariate analysis: p-p70S6K as an independent prognostic factor |
| Choe et al. [26] (45 grade IV) | Anti p-S6 (Ser235/236) ab (CST), diluted 1 : 50 (IHC) | Not provided | — | p- S6 with
(i) EGFRwt
(ii) EGFRvIII
(iii) p-mTOR
(iv) p-ERK | — |
|
